8:30 AM
Opening & Welcome by Chairs
8:45 AM
Chronic Lymphocytic Leukemia
9:00 AM
Indolent Lymphomas
9:15 AM
Aggressive Lymphomas
9:30 AM
Hodgkin Lymphoma
9:45 AM
Panel Discussion + Q&A
8:30 AM
Opening & Welcome by Chairs
Joanna Rhodes, MD, MSCE (Rutgers Cancer Institute of New Jersey) and Jesús Berdeja, MD (Tennessee Oncology)
8:45 AM
CLL
Inhye Ahn, MD (Dana-Farber Cancer Institute)
9:00 AM
Indolent Lymphomas
Ryan Jacobs, MD (Atrium Health Levine Cancer Institute)
9:15 AM
Aggressive Lymphomas
Matt Lunning, MD, FACP (University of Nebraska)
9:30 AM
Hodgkin’s
Boyu Hu, MD (University of Utah Health)
9:45 AM
Community Application Panel Discussion
Michael Byrne, DO (Tennessee Oncology)
10:00 AM
Q&A
10:45 AM
Myeloproliferative Neoplasms and Myelodysplastic Syndrome
11:00 AM
Acute Leukemias
11:15 AM
Multiple Myeloma
11:30 AM
Debate: Is Transplant Still the Best Option for All Eligible Patients?
11:55 AM
Panel Discussion + Q&A
10:45 AM
1L MPNs+MDS
Hetty Carraway, MD, MBA (Cleveland Clinic)
11:00 AM
AML + ALL
Neil Palmisiano, MD, MS (Rutgers Cancer Institute)
11:15 AM
Multiple Myeloma
Peter Voorhees, MD (Atrium Health Levine Cancer Institute)
11:30 AM
Debate: Is Transplant Still the Best Option for All Eligible Patients?
Amrita Krishnan, MD, FACP (City of Hope) and Natalie Callander, MD (University of Wisconsin)
11:55 AM
Community Application Panel Discussion
Tarun Wasil, MD (New York Cancer and Blood Specialists)
12:10 PM
Q&A
1:35 PM
Myeloproliferative Neoplasms
1:50 PM
Myelodysplastic Syndrome
2:05 PM
Multiple Myeloma: Early Relapse
2:20 PM
Debate: Should CART be Used for 2nd Line Therapy?
2:45 PM
Panel Discussion + Q&A
1:35 PM
Multiple Myeloma: Early Relapse
Joshua Richter, MD, FACP (Mount Sinai Health System)
1:50 PM
Debate: Should CART be Used for 2nd Line Therapy?
Krina Patel, MD, MSc (MD Anderson Cancer Center) and Caitlin Costello, MD (University of California San Diego)
2:15 PM
MPNs
John Mascarenhas, MD (Mount Sinai Health System)
2:30 PM
MDS
Amer Zeidan, MBBS (Yale Cancer Center)
2:45 PM
Community Application Panel Discussion
Mindy Hsiao, MD (Tennessee Oncology)
3:00 PM
Q&A
3:45 PM
Optimal Sequencing in Chronic Lymphocytic Leukemia
4:00 PM
Indolent Lymphomas
4:15 PM
Hodgkin Lymphoma
4:30 PM
Aggressive Lymphomas
4:45 PM
Panel Discussion + Q&A
3:45 PM
Optimal Sequencing in CLL
Callie Coombs, MD (University of California-Irvine)
4:00 PM
Indolent Lymphomas
Carla Casulo, MD (James P. Wilmot Cancer Institute)
4:15 PM
Hodgkin’s
Jakub Svoboda, MD (University of Pennsylvania)
4:30 PM
Aggressive Lymphomas
Tycel Phillips, MD (City of Hope)
4:45 PM
Community Application Panel Discussion
Sheila Vasan, MD (Los Angeles Cancer Network)
5:00 PM
Q&A
8:40 AM
Managing Cytokine Release Syndrome in the Community
8:55 AM
Managing Neurotoxicity in the Community
9:10 AM
Preventing and Managing Infections
9:25 AM
Integrating Bispecifics into Practice
9:40 AM
Question & Answer
8:40 AM
Managing CRS in the Community
Oreofe Odejide, MD, MPH (Dana-Farber Cancer Institute)
8:55 AM
Managing Neurotoxicity in the Community
Yi Lin, MD, PhD (Mayo Clinic)
9:10 AM
Preventing and Managing Infections
Noopur Raje, MD (Massachusetts General Hospital)
9:25 AM
Integrating Bispecifics into Practice
Jonathan Abbas, MD (Tennessee Oncology)
9:40 AM
Q&A
10:25 AM
Indolent Lymphomas (including Chronic Lymphocytic Leukemia)
10:40 AM
Aggressive Lymphomas
10:55 AM
Multiple Myeloma: Later Relapse
11:10 AM
Debate: Later Relapse in MM: CAR-T vs. Bispecifics
11:35 AM
Panel Discussion + Q&A
10:25 AM
RRMM 3L+
Susan Bal, MD (University of Alabama Birmingham)
10:40 AM
Debate: Later Relapse in MM: CAR-T vs. Bispecifics
Sham Mailankody, MBBS (Memorial Sloan Kettering Cancer Center) and Ajai Chari, MD (University of California San Francisco)
11:05 AM
Indolent Lymphomas (including CLL)
Alan Skarbnik, MD (Novant Health Cancer Institute)
11:20 AM
Aggressive Lymphomas
Mazyar Shadman, MD, MPH (Fred Hutch Cancer Center)
11:35 AM
Community Application Panel Discussion
Jason Chandler, MD (West Cancer Clinic)
11:50 AM
Q&A
1:15 PM
Healthcare Policy
1:30 PM
Measurable Residual Disease in Hematologic Malignancies
1:45 PM
Defining High Risk Disease in Hematologic Malignancies
2:00 PM
Dealing with Drug Shortages in Oncology
2:15 PM
Diversity, Equity, and Inclusion in Hematologic Malignancies
2:30 PM
Bringing CAR-T to the Community
2:45 PM
Question & Answer
1:15 PM
Healthcare Policy
Stephen Schleicher, MD, MBA (Tennessee Oncology)
1:30 PM
MRD in Hematologic Malignancies
Hearn Cho, MD, PhD (Mount Sinai Health System)
1:45 PM
Defining High Risk Disease in Hematologic Malignancies
Faith Davies, MD, MBBCh (NYU Langone Health)
2:00 PM
Dealing with Drug Shortages in Oncology
Jason Westin, MD (MD Anderson Cancer Center)
2:15 PM
DEI in Heme Malignancies
Christopher Flowers, MD, MS (MD Anderson Cancer Center)
2:30 PM
Special Guest
Natalie Dickson, M.D., MMHC, FACP (Tennessee Oncology)
2:45 PM
Q&A
3:30 PM
Multiple Myeloma
3:45 PM
Chronic Lymphocytic Leukemia
4:00 PM
Indolent Lymphomas
4:15 PM
Aggressive Lymphomas
4:30 PM
Myeloproliferative Neoplasms and Myelodysplastic Syndrome
4:45 PM
Acute Leukemias
3:30 PM
Multiple Myeloma
Adam Cohen, MD (University of Pennsylvania)
3:45 PM
CLL
Jacqueline Barrientos, MD, MS (Mount Sinai Health System)
4:00 PM
Indolent Lymphomas
Elise Chong, MD (University of Pennsylvania)
4:15 PM
Aggressive Lymphomas
Sarah Rutherford, MD (Weill Cornell Medicine)
4:30 PM
MPNs + MDS
Andrew Kuykendall, MD (Moffitt Cancer Center)
4:45 PM
AML + ALL
Alexander Perl, MD (University of Pennsylvania)
*Agenda is subject to change.
Experience Nashville, TN
